Impact of a human papillomavirus vaccination clinical program in a commercially insured population
The difference observed between cohorts for the proportion of members who completed the series was not statistically significant. Cohorts B and C completed the series later compared with Cohort A, and a higher proportion received doses 1 and 2 more than 1 year apart. Although the years 2020 and 2021 were not included, lasting impact from the pandemic may have influenced study results; however, BCBSM's efforts may have mitigated the impact of the national decrease seen in HPV vaccination among in-state members.
Authors
- Meilan Mo (ORCID: https://orcid.org/0000-0003-3903-0509)
- Karli Pelaccio (ORCID: https://orcid.org/0000-0001-9622-4911)
- Allison Olmsted
- Kelly DeJager
Institutions
- Blue Cross Blue Shield of Michigan Foundation (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2024-11-29
- DOI
- https://doi.org/10.18553/jmcp.2024.30.12.1405
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00